Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

Sponsor
University of Washington (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05911243
Collaborator
National Center for Complementary and Integrative Health (NCCIH) (NIH), National Center for Advancing Translational Sciences (NCATS) (NIH)
66
1
2
15
4.4

Study Details

Study Description

Brief Summary

This clinical trial evaluates the feasibility and acceptability of acupressure to the ear (auricular) to address appetite and weight in patients with stage II-IV gastric, esophageal, or pancreatic cancer. Cancer anorexia, the abnormal loss of appetite, directly leads to cancer-associated weight loss (cachexia) through malnourishment, reduced caloric intake, treatment side-effects, and other modifiable risk factors. Cachexia prolongs length of hospital stay for patients, negatively impacts treatment tolerance and adherence, and reduces overall patient quality of life. Auricular acupressure is a form of micro-acupuncture that exerts its effect by stimulating the central nervous system using adhesive taped pellets applied to specific locations on the external ear. The use of these pellets to deliver auricular acupressure has been shown to improve pain, fatigue, insomnia, nausea and vomiting, depression, and quality of life in both cancer and non-cancer settings. Auricular acupressure is a safe, inexpensive, and non-invasive approach to addressing cancer-related symptoms and treatment side-effects and may be effective at improving appetite and weight loss in stage II-IV gastric, esophageal, and pancreatic cancer patients.

Detailed Description

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.

ARM II: Patients receive usual care on study. Patients also undergo collection of blood samples on study.

After completion of study treatment, patients in Arm II are followed up at 8 weeks after active treatment ends.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
A Randomized Controlled Trial Testing the Effects of an Acupressure Intervention on Appetite and Weight in Patients With Gastric, Esophageal, and Pancreatic Cancer: A Pilot and Feasibility Study
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Nov 30, 2024
Anticipated Study Completion Date :
Jan 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm I (acupressure therapy)

Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.

Procedure: Acupressure Therapy
Undergo auricular acupressure
Other Names:
  • Acupressure
  • Ischemic Compression
  • Other: Best Practice
    Receive usual care
    Other Names:
  • standard of care
  • standard therapy
  • Procedure: Biospecimen Collection
    Undergo collection of blood samples
    Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Other: Questionnaire Administration
    Ancillary studies
    Other Names:
  • Quality of Life Assessment
  • Active Comparator: Arm II (usual care)

    Patients receive usual care on study. Patients also undergo collection of blood samples on study.

    Other: Best Practice
    Receive usual care
    Other Names:
  • standard of care
  • standard therapy
  • Procedure: Biospecimen Collection
    Undergo collection of blood samples
    Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Other: Questionnaire Administration
    Ancillary studies
    Other Names:
  • Quality of Life Assessment
  • Outcome Measures

    Primary Outcome Measures

    1. Accrual (feasibility) [Up to 15 months]

      Accrual will be measured by the average rate of participants-per-month enrolled into both groups with the goal of 5 patients/month over a 15-month period.

    2. Retention (feasibility) [Up to 8 weeks]

      Retention will be measured by the number of participants who remain in the trial and provide data at the closeout visit.

    3. Intervention adherence (feasibility) [Up to 8 weeks]

      Adherence will be measured in the intervention group by the number of applied auricular acupressure treatments, with the total possible being 8.

    4. Intervention fidelity (feasibility) [Up to 8 weeks]

      Fidelity will be assessed by study team adherence to symptom query and appropriate ear seed point modifications to the standard protocol and accuracy of seed placement according to photographic analysis.

    5. Acceptability (feasibility) [Up to 16 weeks]

      Acceptability will be assessed using a random convenience sample of participants and providers through semi-structured interviews.

    Secondary Outcome Measures

    1. Change in appetite [Baseline to week 4]

      As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 4.

    2. Change in appetite [Baseline to week 8]

      As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 8.

    3. Change in body weight (kg) [Baseline to week 4]

      Analyses will assess change in each outcome as a change from baseline to week 4.

    4. Change in body weight (kg) [Baseline to week 8]

      Analyses will assess change in each outcome as a change from baseline to week 8.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 18-65 years of age

    • Stage II-IV gastric, esophageal, or pancreatic cancer

    • Appetite score on visual analog scale =< 70/100

    • Functional Assessment for Anorexia/Cachexia Treatment Subscale (FACT-ACS) score < 37

    • At least 60 days of planned systemic treatment, whether already initiated or scheduled to be initiated

    • Access to phone and electronic device for study contacts and questionnaires

    • Willing and able to attend 4 in-person auricular acupressure treatments at the Fred Hutch South Lake Union Clinic

    • Willing and able to perform 4 at-home self-applied treatments of auricular acupressure

    • Participants must not have received acupressure or acupuncture for low appetite within last 30 days

    • Participants must not be actively using corticosteroids or immunomodulators for appetite stimulation at baseline

    • Participants must be able to intake food orally and not require sole or supplemental intravenous nutrition at baseline

    • Participants must not have a history of physiological eating disorders (e.g., anorexia nervosa) in the last 3 years

    • Participants must not have a current known or diagnosed immunodeficiency

    • Participants must have an intact auricular pinna

    • Able to understand and willing to sign written informed consent in English

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fred Hutch/University of Washington Cancer Consortium Seattle Washington United States 98109

    Sponsors and Collaborators

    • University of Washington
    • National Center for Complementary and Integrative Health (NCCIH)
    • National Center for Advancing Translational Sciences (NCATS)

    Investigators

    • Principal Investigator: Blake Langley, Fred Hutch/University of Washington Cancer Consortium

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Washington
    ClinicalTrials.gov Identifier:
    NCT05911243
    Other Study ID Numbers:
    • RG1123492
    • NCI-2023-03942
    • RG1123492
    • 3KL2TR002317
    First Posted:
    Jun 20, 2023
    Last Update Posted:
    Jun 20, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 20, 2023